Analysts' ratings for Danaher (NYSE:DHR) over the last quarter vary from bullish to bearish, as provided by 5 analysts.

The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.

The 12-month price targets, analyzed by analysts, offer insights with an average target of $275.0, a high estimate of $290.00, and a low estimate of $260.00. Experiencing a 6.78% decline, the current average is now lower than the previous average price target of $295.00.

Investigating Analyst Ratings: An Elaborate Study

The standing of Danaher among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Danaher's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.

Stay up to date on Danaher analyst ratings.

Get to Know Danaher Better

In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Then, through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in the life science and diagnostic industries after the late 2023 divestiture of its environmental and applied solutions group, Veralto.

Danaher: Delving into Financials

Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.

Revenue Growth: Danaher's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 3.09%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.

Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 14.11%, the company showcases strong profitability and effective cost control.

Return on Equity (ROE): Danaher's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.62% ROE, the company effectively utilizes shareholder equity capital.

Return on Assets (ROA): Danaher's ROA stands out, surpassing industry averages. With an impressive ROA of 1.03%, the company demonstrates effective utilization of assets and strong financial performance.

Debt Management: Danaher's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.34.

Analyst Ratings: Simplified

Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.

Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.

Breaking: Wall Street's Next Big Mover

Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.

This article was generated by Benzinga's automated content engine and reviewed by an editor.